LabGenius and Sanofi Expand AI-Driven Antibody Partnership with New NANOBODY Optimization Collaboration
核心洞察
LabGenius Therapeutics (搜索) has entered a second collaboration with Sanofi to apply its EVA™ machine learning platform for optimizing NANOBODY (搜索) proteins targeting multiple inflammatory disease targets.
The partnership builds on their successful 2021 collaboration, where LabGenius demonstrated that optimized NANOBODY (搜索) candidates met success criteria while maintaining strong production characteristics for commercial viability.
NANOBODY (搜索) molecules offer unique therapeutic advantages due to their ultra-small size, allowing access to targets inaccessible to classical antibodies and enabling multivalent constructs for multi-action therapeutic approaches.
LabGenius Therapeutics (搜索) has announced a second collaboration with Sanofi, expanding their partnership to apply machine learning-driven antibody optimization to multiple new inflammatory targets (搜索) using NANOBODY (搜索) proteins. The agreement represents continued validation of AI-first drug discovery approaches in synthetic antibody engineering, where speed, precision and manufacturability determine program success.
Building on Proven Success
The new collaboration builds on the companies' initial 2021 partnership, which combined LabGenius' strengths in machine learning, robotic automation and synthetic biology with Sanofi's expertise in engineering NANOBODY (搜索) heavy chain variable domains. LabGenius will apply its EVA™ platform to optimize potential therapeutic NANOBODY proteins for multiple new targets in the area of inflammation (搜索).
The original collaboration demonstrated measurable success. In 2023, LabGenius presented data at the Single-Domain Antibodies Meeting confirming that a panel of optimized NANOBODY (搜索) candidates met the collaboration's success criteria while maintaining strong production characteristics—a key requirement for commercial viability.
NANOBODY Therapeutic Advantages
NANOBODY (搜索) molecules represent ultra-small antibody fragments derived from species that naturally produce heavy-chain-only antibodies. Their size provides access to targets inaccessible to classical antibodies, and they can be linked like "beads on a string" to create multivalent constructs capable of simultaneously binding multiple disease-relevant proteins.
These characteristics have driven significant biopharma interest because the formats can consolidate multi-drug regimens into single, multi-action therapeutic molecules. Their stability also opens possibilities for new delivery routes, including potential oral formulations.
Platform Validation and Market Position
"We are truly excited about this new collaboration with Sanofi," said LabGenius' CSO, Dr. Angus Sinclair. "This partnership serves as strong validation of our platform's unique ability to tackle complex antibody co-optimization challenges across a wide range of therapeutic targets, ultimately driving better outcomes for patients."
For investors monitoring the computational biology space, the deal signals accelerating confidence in AI-first drug discovery, particularly in synthetic antibody engineering. The ability to systematically optimize NANOBODY (搜索) properties—binding, solubility, expression, stability and immunological performance—represents a significant competitive advantage.
Technology Integration
LabGenius' EVA™ platform integrates artificial intelligence, high-throughput robotic experimentation and synthetic biology to explore millions of possible antibody variants and identify combinations that yield the best-performing molecules. Over the multi-year original program, LabGenius used its platform to explore vast mutational landscapes and co-optimize these small but highly versatile proteins for predefined therapeutic characteristics.
The company continues to operate a hybrid business model, partnering with biotech and pharmaceutical companies while pursuing a wholly-owned therapeutic pipeline. As AI-driven protein design matures, collaborations like this provide real-world testing grounds for how machine learning can shorten development timelines and improve the quality of biologics entering development.